Rigel Pharmaceuticals, Inc. (RIGL)
- PR Newswire
Rigel Announces Closing of Strategic Collaboration with Lilly
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Rigel and Lilly entered a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. Pursuant to the collaboration, Lilly will also lead all clinical development of penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.
- PR Newswire
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova Health System. Fostamatinib is marketed in the U.S. as TAVALISSE® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
- Simply Wall St.
Need To Know: Analysts Are Much More Bullish On Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Revenues
Shareholders in Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) may be thrilled to learn that the analysts have just...
